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(57) ABSTRACT 
Methods of encapsulating cargo in a micro gel droplet, micro-
gel droplets prepared according the provided methods, and 
methods of use thereof are disclosed. The methods of prepar-
ing cargo-encapsulated microgels generally include flowing 
through a flow-focusing nozzle of a microfluidic device a 
macromer phase, an oil phase, and a crosslinker phase to form 
microgel droplets by oil-water emulsion. The phases are 
pumped, injected, or flowed through the microfluidic device 
such that as the macromer phase approaches the flow focusing 
nozzle, the co-flowing oil phase shields the macromer from 
contact with the crosslinker phase until flow instability occurs 
and macromer phase droplets form. After flow instability 
occurs, the crosslinker diffuses from the crosslinker phase 
into the droplets in an effective amount to covalently 
crosslink the macromer into a microgel network encapsulat-
ing the cargo in the crosslinked macromer. Microgels pre-
pared according to the disclosed methods and methods of use 
thereof are also provided. 
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MICROGELS FOR ENCAPSULATION OF 
CELLS AND OTHER BIOLOGIC AGENTS 
2 
Chip, 8(7): 1110-5 (2008). However, translating this work 
into covalently crosslinking of microgels within microfluidic 
devices adds significant complexity because polymer precur-
sors must be liquid while flowing through the focusing CROSS-REFERENCE TO RELATED 
APPLICATIONS 5 nozzle, but droplets must crosslink rapidly after being gener-
ated to prevent them from merging. 
Synthetic polymer microgels have been generated, includ-
ing cell-laden micro gels (Rossow, et al., Journal of the Ameri-
can Chemical Society, 134(10):4983-9 (2012), Velasco, eta!., 
This application claims priority to and benefit ofU.S. Pro-
visional Patent Application No. 61/875,287 filed on Sep. 9, 
2013, and where permissible is incorporated by reference in 
its entirety. 
REFERENCE TO SEQUENCE LISTING 
The Sequence Listing submitted Sep. 9, 2014 as a text file 
named "GTRC_6467_ST25.txt," created on Sep. 9, 2014, 
and having a size of 1, 723 bytes is hereby incorporated by 
reference pursuant to 37 C.F.R. §1.52(e)(5). 
10 Small, 8(11):1633-42 (2012), Allazetta, et al., Bio macromol-
ecules, 14(4):1122-31 (2013), Panda, et al., Lab Chip, 8(7): 
1056-61 (2008), Chung, et al., Applied Physics Letters, 
91:041106 (2007) Kesselman, et al., Small, 8(7):1092-8 
(2012), Tumarkin, et al., Chemical Society Reviews, 38(8): 
FIELD OF THE INVENTION 
15 2161-8 (2009)). However, even for synthetic polymer encap-
sulation, control of cellular microenvironment by functional-
ization of polymers with bioactive molecules remains a 
significant challenge. Most of these schemes require 
crosslinking using UV-based free radical polymerization, 
The invention is generally directed to methods of encapsu-
lating cells and other bioactive agents in microgel droplets, 
microgel droplet therefrom, and methods of use thereof. 
20 resulting in potentially cytotoxic effects on encapsulated 
cells. Although cell encapsulation in synthetic microgels 
crosslinked without free radicals has been reported, the poly-
mer cam10t easily be functionalized with bioactive molecules 
(Rossow, et al., Journal of the American Chemical Society, 
BACKGROUND OF THE INVENTION 25 134(10):4983-9 (2012), Kesselman, et al., Small, 8(7): 1092-8 
(2012)). This major limitation makes the maintenance of cells 
requiring adhesive ligands for viability and function difficult. 
Lutolf devised a microfluidic scheme to generate surface-
modifiable synthetic micro gels that does not utilize free radi-
Hydrogel microencapsulation of cells is a promising strat-
egy for immunoprotection after transplantation. Since the 
development of alginate-poly-L-lysine encapsulation by Lim 
and Sun in 1980 (Lim, et al., Science 210(4472):908-10 
(1980)), their approach has remained the standard for cell 
encapsulation, although major efforts have led to improve-
ments (T. Wang, eta!., Nature Biotechnology, 15:358 (1997)). 
The ease of alginate microencapsulation, along with algi-
nate's inherent biotolerance in vivo, has led to its prevalence 35 
(E. Santos, et al., J. Control, 170:1 (2013)), even though the 
ability to control local cellular environment via incorporation 
30 cal polymerization, but neither bulk modification with bioac-
tive molecules nor cell encapsulation was shown (Allazetta, 
et al., Biomacromolecules, 14(4):1122-31 (2013), Panda, et 
al., Lab Chip, 8(7):1056-61 (2008), Chung, et al., Applied 
Physics Letters, 91:041106 (2007)). 
Microfluidic encapsulation of large clusters of cells, such 
as human islets, is more challenging than single cell encap-
sulation, because the larger particles tend to clog microfluidic 
channels. To minimize encapsulation volume while avoiding 
microfluidics altogether, investigators have explored confor-
40 ma! coating of islets (Blasi, et al., International Journal of 
Pharmaceutics, 440(2):141-7 (2013), Teramura, et al., Bio-
materials, 34(11):2683-93 (2013)). Whereas conformal coat-
ing minimizes transplant volume, the immunoisolation 
of bioactive molecules (e.g., adhesive peptides) is limited. 
Highly tunable, synthetic hydro gel encapsulation is attractive 
for various regenerative medicine applications (Lutolf, et al, 
Nat Biotechnol, 23(1):47-55 (2005), Peppas, et al., Science, 
263(5154):1715-20 (1994); Langer, et al., Nature, 
428(6982):487-92 (2004)), not onlyforimmunoisolation, but 
also for directing cell behavior and fate (Lutolf, et al, Nat 
Biotechnol, 23(1):47-55 (2005)). Several groups have <level- 45 
oped more complex encapsulation configurations, such as 
cell encapsulation in natural hydrogel fibers (Onoe, et al., 
Nature Materials, 12(6):584-90 (2013); Jun, et al., Biomate-
rials, 34(33):8122-30 (2013)), but the benefits of added geo-
metric complexity remain to be established. 
potential of such thin polymer membranes remains unknown. 
Thus there remains a need for improved, biocompatible 
methods of encapsulating cells and other biological agents in 
microgels. 
It is therefore an object of the invention to provide a tun-
able, biocompatible platform for packaging cells and/or other 
50 biological agents, including, but not limited to, peptides, pro-
teins, nucleic acids, and other biomolecules, into microgels. Minimization of encapsulation volume is also important in 
many regenerative medicine scenarios, including pancreatic 
islet transplantation. In an effort to reduce the high polydis-
persity present in electro statically generated alginate droplets 
with diameters <200 µm (Goosen, et al., J. Microencapsul., 55 
13(5):497-508 (1997)), microfluidic droplet generation has 
been explored (Choi, et al., Biomed Microdevices, 9(6):855-
62 (2007); Tan, et al., Advanced Materials, 19:2696 (2007); 
Um, et al., Micro.fluid Nano.fluid, 5:541 (2008)). Microfluidic 
devices have also been used to generate synthetic hydrogel 60 
particles (Rossow, et al., Journal of the American Chemical 
Society, 134(10):4983-9 (2012), Velasco, et al., Small, 8(11): 
1633-42 (2012), Allazetta, et al., Biomacromolecules, 14( 4): 
1122-31 (2013), Panda, et al., Lab Chip, 8(7):1056-61 
(2008), Chung, et al., Applied Physics Letters, 91:041106 65 
(2007) ). Weitz established encapsulation of cells inside emul-
sions for high throughput cell-based assays Koster, et al., Lab 
It is a further object of the invention to provide a tunable, 
biocompatible platform for packaging multiple cells, for 
example cell clusters or islets, into a single micro gel droplet. 
It is anotherobject of the invention to provide compositions 
including microgel encapsulated cells and other biological 
agents. 
It is another object of the invention to provide methods of 
using microgel encapsulated cells and both biological agents. 
SUMMARY OF THE INVENTION 
Methods of encapsulating cargo in a microgel droplet, 
microgel droplets prepared according to the provided meth-
ods, and methods of using the micro gels are disclosed. The 
methods of preparing cargo-encapsulated microgels gener-
ally include flowing a macromer phase, an oil phase, and a 
US 9,381,217 B2 
3 
crosslinker phase through a flow focusing nozzle of a microf-
luidic device to form microgel droplets by oil-water emul-
sion. The macromer phase typically includes a macromer and 
a cargo in aqueous buffer; the oil phase typically includes an 
oil and a surfactant; and the crosslinker phase includes an oil, 
4 
examples, the functionalize moiety is a peptide including an 
RGD ligand for integrins to enhance cell adhesion and sur-
vival. In some embodiments, the bioactive agent is a thera-
peutic drug which can be released from the microgel by a 
protease or other enzymes in vivo. 
Microgel droplets prepared according to the disclosed 
methods can be used for myriad of therapeutic applications 
by administering an effective amount of the microgels to a 
subject in need thereof. For example, in a particular embodi-
a surfactant, and a crosslinking agent. The phases are 
pumped, injected, or passaged through the microfluidic 
device such that as the macromer phase approaches the flow 
focusing nozzle, the co-flowing oil phase shields the mac-
romer from contact with the crosslinker phase until flow 
instability occurs and macromer phase droplets form. After 
flow instability occurs, the crosslinker diffuses from the 
crosslinker phase into the droplets in an effective amount to 
covalently crosslink the macromer into a microgel network 
encapsulating the cargo in the crosslinked macromer. 
10 ment, the microgels encapsulate insulin secreting pancreatic 
beta cell islets which can be transplanted into a subject to treat 
diabetes. In another embodiment, the microgel serves as a 
drug delivery vehicle or drug deport and can be used to 
administer a subject an effective amount of a bioactive agent 
15 to treat a disease or disorder such as cancer or an infection. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. lA is reaction diagram showing the structure of a 
PEG-4MAL macromer including a 4-arm branched PEG 
backbone modified with a maleimide group terminating each 
arm. At physiological pH, free thiol-containing molecules 
undergo a Michael-type addition reaction with maleimides, 
forming a covalent bond to macromer. This reaction is facili-
The method can be fine-tuned to control the size and per-
meability of the microgel droplet. For example, the nozzle 
size and flow rates can be selected to produce droplets of a 
size between about 10 µm and 1,000 µm, inclusive. In a 
particular embodiment, the macromer is a four arm maleim- 20 
ide-linked polyethylene glycol (PEG-4MAL). A preferred 
crosslinker includes a thiol that can be covalent crosslinked to 
the maleimide by a Michael-type additional reaction, for 
example, dithiothreitol (DTT), or a biodegradable peptide 
crosslinker. In some embodiments, the peptide includes a 
cleavage site for one or more proteases or other enzymes. In 
this way, release of the cargo from the microgel can be con-
trolled by contacting the microgels with the protease or 
enzyme. The contacting with the protease or enzyme can 
occur in vivo. In some embodiments, the protease or enzyme 
25 tated by nucleophilic buffers such as triethanolamine (TEA), 
and can be used to either functionalize the macromer or 
crosslink macromer into a hydrogel network. FIG. lB is a 
schematic of a microfluidic device with flow focusing geom-
etry utilized to produce microgels according to the disclosed 
is upregulated in a disease or disorder state, or in diseased or 
dysfunctional tissue such that cargo is released from the 
microgel when the disease or disorder is active and/or when 
the microgel comes in close proximity of the diseased or 
dysfunctional tissue. Exemplary peptide crosslinkers include, 
but are not limited to, peptides including the amino acids of 
SEQ ID NOS:4, 5, or 6, or a variant thereof with at least 70%, 
80%, 85%, 90%, 95%, or more sequence identity to SEQ ID 
N0:4, 5, or 6, and which preferably includes two cysteines, 
and can be cleaved by one or more proteases. 
30 methods. A co-flowing oil phase shields an aqueous mac-
romer solution, containing cells and/or other bioactive agents 
such a proteins, from the crosslinker-containing oil phase as 
the macromer solution approaches the flow focusing nozzle. 
After droplet formation, the crosslinker (e.g., DTT) emulsion 
35 rapidly crosslinks macromere solution into cell- or protein-
laden microgels. 
FIG. 2A is a series of representative images and quantifi-
cation of microgel diameters for corresponding varied flow 
rates. FIGS. 2B-2E are line graphs showing the droplet size 
The permeability can be adjusted by, for example, altering 
the size of the macromer and type of crosslinker used. The 
Examples below illustrate that a micro gel network formed of 
40 (µm) as a function of various macromerphase flow rates (1, 5, 
10, 20, 30 QPEdµmin- 1 ) and crosslinkerphase flow rates (10, 
20, 30, 50, 100, 200, 400 ~linJµmin- 1 ) for oil phase flow 
rates (Q0 a) of 5 µmin- 1 (2B), 25 µmin- 1 (2C), 50 µumin- 1 
(2D), 100 µmin- 1 (2E). Mean and standard error were plotted 10 kDa PEG-4MAL is generally impermeable to macromol-
ecules such as IgG, while a network formed of a 20 kDa 
PEG-4MAL is somewhat more permeable to IgG. The per-
meability of the microgel can be adjusted based on the appli-
cation. For example, the permeability of the microgel can be 
selected based on a desired release rate of a bioactive agent 
encapsulated therein. In other embodiments, the permeability 50 
is selected to prevent antibodies and immune cell from reach-
ing encapsulated cells, while nutrients, signaling molecules, 
and waste can be transported across the microgel capsule. 
45 as calculated from a minimum of 30 measurements for each 
The methods can be used to encapsulate a single cell, 
clusters of cells including islets, and other bioactive agents 55 
including, but not limited to, proteins, peptides, amino acids, 
nucleic acids, carbohydrates, lipids, small molecules, or com-
binations thereof. The method is particularly well suited for 
preparing viable, microencapsulated monodispersed multi-
cell islets. The methods are also particular useful for drug 60 
delivery, particularly of macromolecular drugs such as pep-
tide and protein based therapeutic agents. 
In some embodiments, the macromer is functionalized 
prior to crosslinking. In a particularly preferred embodiment, 
this is accomplished by reacting a bioactive active agent with 65 
a thiol group (e.g., a protein or peptide with cysteine) with a 
maleimide on the macromere prior to crosslinking. In some 
condition. 
FIG. 3A is a line graph showing the release kinetics (% 
release) for biomolecules of varying size (glucose, insulin, 
BSA, IgG) from microgels (made with 20 kDa macromers). 
FIG. 3B is a line graph showing the % release of IgG from 
microgels made with 20 kDa macromers verses the% release 
oflgG from microgels made with 10 kDa. FIG. 3C is a series 
of representative pictomicrograph showing human islets in 
culture after encapsulation (days 1, 2, 5, and 8 after microen-
capsulation) (scale bars=200 µm). FIG. 3D is a line graph 
showing the viability of human islets in culture 1, 2, 5, and 8 
after microencapsulation, quantified using fluorescent area 
ratios between TOT0-3 iodide (dead) and calceinAM (live). 
FIG. 3E is a series ofrepresentativepictomicrograph showing 
human mesenchymal stem cells (hMSC) that were encapsu-
lated in micro gels of various sizes (scale bars=! 00 µm). FIG. 
3F is a line graph showing the viability ofhMSC in culture 1, 
2, 3, 4, and 8 after microencapsulation in 400 µm microgels. 
FIG. 3G is a bar graph showing the glucose stimulation index 
measured by a glucose stimulated insulin secretion assay for 
bare and microencapsulated cells one day after human islet 
encapsulation. 
US 9,381,217 B2 
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FIG. 4A is a line graph showing the microgel diameter 
(µm) as a function of PEG flow rate (µI/min) for various 
crosslinker flow rates (100, 150, 225, 300 µI/min). FIG. 4B is 
a bar graph showing islet viability (fold of control) for 
unmodified cells (left hand bar) and cells encapsulated in 
microgels (right hand bar). FIG. 4C is a bar graph showing 
glucose-stimulated insulin response (GSIR) (µg/dL) of islets 
encapsulated in PEG hydrogels as compared to unmodified 
islets at various time points. Glucose concentration (mM) 
administered over time is indicated by a line. For each time 10 
point, unmodified islets are represented with the left hand bar 
and islets encapsulated in PEG hydrogels are represented 
with the right hand bar. FIG. 4D is a line graph showing 
diabetes reversal time between unmodified(-•-) and PEG-
encapsulated (-+-)islets following syngeneic minimal islet 15 
mass transplant into diabetic mice. 
FIG. SA a schematic of a microfluidic device with flow 
focusing geometry utilized to produce microgels according to 
the disclosed methods. A co-flowing oil phase shields an 
aqueous macromer solution, containing cargo, from the 20 
crosslinker-containing oil phase as the macromer solution 
approaches the flow focusing nozzle. After droplet formation, 
the crosslinker (e.g., DTT, or a cysteine-containing peptide) 
emulsion rapidly crosslinks macromere solution into cargo-
laden microgels. FIG. SB is a line graph showing protein 25 
release from microgels crosslinked by different peptides 
crosslinkers (GPQ(W) (SEQ ID N0:2) (-+-)and VPM (-•-) 
and GPQ(A) (SEQ ID N0:3) (-... -))over the time as they are 
degraded in the presence of protease (collagenase I). 
6 
logic and/or physiologic effect. The precise dosage will vary 
according to a variety of factors such as subject-dependent 
variables (e.g., age, immune system health, etc.), the disease 
or disorder being treated, as well as the route of administra-
tion and the pharmacokinetics of the agent being adminis-
tered. 
As used herein, the term "prevention" or "preventing" 
means to administer a composition to a subject or a system at 
risk for or having a predisposition for one or more symptom 
caused by a disease or disorder to cause cessation of a par-
ticular symptom of the disease or disorder, a reduction or 
prevention of one or more symptoms of the disease or disor-
der, a reduction in the severity of the disease or disorder, the 
complete ablation of the disease or disorder, stabilization or 
delay of the development or progression of the disease or 
disorder. 
II. Platform for Encapsulation of Cells and Other 
Biological Agents 
A modular, two-phase (oil-water) microfluidics-based 
platform for the generation ofhydrogel microsphere (micro-
gel) droplets of controlled size and permeability using is 
provided. Microgel droplets encapsulating cells and/or other 
biological agents, such as peptides, proteins, nucleic acids, 
etc., prepared according to the disclosed platform, and meth-
ods of use thereof are also provided. 
The platform typically includes a microfluidic device with 
a flow focusing nozzle and three independent flows: (1) a 
DETAILED DESCRIPTION OF THE INVENTION 
I. Definitions 
30 polymer or macromer phase including a polymer and a cargo, 
typically cells and/or one or more other bioactive agents, 
typically in aqueous, physiological buffer; (2) an oil phase 
containing a surfactant; and (3) a crosslinker phase contain-
ing oil and surfactant with an emulsion of crosslinker solu-
As used herein, "polymer" refers to a molecule consisting 
of a number of repeating units. 
As used herein, "repeat unit" refers to the fundamental 
recurring unit of a polymer. 
As used herein, "monomer" refers to the smaller 
molecule( s) that are used to prepare a polymer. It may or may 
not be equivalent to the repeat unit. 
As used herein, "macromer" and "macromonomer" refers 
to any polymer or oligomer that has a functional group that 
can take part in further polymerization. 
35 tion. As used herein "polymer" and "macromer" are used 
interchangeable to refer to the subunits that are crosslinked to 
form the microgel. Therefore, the "polymer phase" can be a 
"macromer phase" and vice versa depending on the subunit 
that is selected. However, it will be appreciated that the poly-
40 mer or macromer used in the polymer/macromer phase is 
capable of being crosslinked or further polymerized by a 
crosslinker in the crosslinker phase to form a micro gel drop-
let. 
A. Methods of Making Micro gels 
As used herein, "microgel" refers to a gel formed from a 45 
network of microscopic filaments of polymer or macromer. 
The three phases are flowed or pumped into a microfluidic 
device with flow focusing geometry. In a particular embodi-
ment, the microfluidic device is a polydimethylsiloxane 
(PDMS) microchip (Fujii, et al., Microelectronic Engineer-
ing, 61-62:907-914 (2002)). The three fluid phases can be 
As used herein, "subject or patient" refers to a mammal, 
primate and preferably a human. 
flowed or pump through the microfluidic device using any 
suitable means. In preferred embodiments the phases are 
delivered by pumps, for example syringe pumps. Exemplary 
microfluidic devices are schematized in FIGS. lB and SA. 
As the macromer phase approaches the flow-focusing 
As used herein, "implant", refers widely to any type of 
implanted or implantable foreign object or material. Implants 50 
also include objects or materials that are nearly identical to 
non-foreign objects or materials. The implant according to 
the invention is not limited to any particular shape. The final 
shape of the implant in the body is decided by the skilled man 
from the purpose of the treatment. 55 nozzle, a co-flowing continuous phase of oil shields the mac-
romer from contact with the crosslinker phase until flow 
instability occurs. The crosslinker then rapidly diffuses into 
droplets, covalently crosslinking the macromer into a micro-
As used herein, the term "carrier" or "excipient" refers to 
an organic or inorganic ingredient, natural or synthetic inac-
tive ingredient in a formulation, with which one or more 
active ingredients are combined. 
As used herein, the term "pharmaceutically acceptable" 60 
means a non-toxic material that does not interfere with the 
gel network encapsulating the cells or other bioactive agent in 
the crosslinked polymer. Because crosslinker cannot reach 
the macromer before flow instability occurs, monodisperse, 
effectiveness of the biological activity of the active ingredi-
ents. 
As used herein, the terms "effective amount" or "therapeu-
tically effective amount" means a dosage sufficient to allevi-
ate one or more symptoms of a disorder, disease, or condition 
being treated, or to otherwise provide a desired pharmaco-
spherical microgel droplets can be formed in this manner. 
Outlet channel length can be used to control the residence 
time of the generated droplets inside the device. For example, 
65 increasing the length of the channel increases the residence 
time of the generated droplets inside the device. The molar 
ratio of the macromer:crosslinker and pH of the fluids can be 
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modulated to control the kinetics of the gelation after contact 
of both phases in the microfluidic device. The length of the 
channel in combination with the kinetics of gelation can be 
fine-tuned to ensure micro gel formation before the macromer 
droplets leave the device. The macromer and crosslinker, 
which are discussed in more detail below, are used in concen-
trations and ratios that are effective for form microgels. 
8 
larger proteins BSA and IgG, the release did not reach 50% of 
the incorporated amount because these larger molecules 
remain trapped within the tight network structure of the PEG 
hydro gel. 
The Examples also illustrate that a tighter network mesh of 
the microgels based on 10 kDa marcomer slowed the release 
of encapsulated IgG compared to microgels made with 20 
kDa macromer. It is believed that not only macromer size, but 
also other parameters of the composition and method of mak-
10 ing the microgel, including, but limited to, the polymer 
weight % and crosslinking density, can be systematically 
varied alone or in any combination, to obtain and fine tune 
desired release kinetics. These parameters can be modulated 
by varying compositions, such as the macromer and 
The platform is used to prepare microgel encapsulated 
cargo. In the most preferred embodiment, the cargo is cells 
and/or one or more other bioactive agents. Therefore, oil, 
surfactant, macromer and crosslinker are typically used in 
concentrations that are biocompatible with the cells or bioac-
tive agents they are being used to encapsulate. For example, 
preferably the oil, surfactant, macromer and/or crosslinker 
does not substantially damage or kill the cells, or substantially 
reduce, inhibit, or inactive the bioactive agent. Preferably at 
least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 
95%, 99%, or more than 99% of the loaded cells remain 
viable following encapsulation. Preferably at least 20%, 30%, 
40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or more 20 
than 99% of the loaded bioactive agent remains active or 
functional following encapsulation. 
15 crosslinker as described in more detail below. These release 
As discussed herein microgel droplets prepared according 
the disclosed methods can be polydispersed or monodis-
persed. Dispersity, as used herein refers, to a measure of the 25 
heterogeneity of sizes of microgels in a mixture (e.g., a com-
position including at least two micro gel droplets). Therefore, 
monodispersed compositions are typically composed of 
microgels that are predominately essentially the same size, 
while poly dispersed compositions are typically composed of 30 
microgels of different sizes. In some embodiments, the 
method can be used to prepare a population of micro gels that 
is at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 
or more essentially the same size. Therefore, compositions 
having microgels, wherein at least 50%, 60%, 70%, 75%, 35 
80%, 85%, 90%, 95%, 99% or more of the micro gels are at 
least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 
more essentially the same size are also provided. Microgels 
can be considered to be essentially the same size when they 
are between about 50% and about 150%, or between about 40 
60% and about 140%, or between about 30% and about 
130%, or between about 20% and about 120%, or between 
about 10% and about 110%, or between about 95% and about 
105% of the size of a reference microgel or desired micro gel 
size. Preferred sizes depend on the intended use and are 45 
discussed in more detail below. 
B. Methods of Tuning Microgel Parameters 
As illustrated in the Examples below, certain parameters of 
the microfluidic-based methods of making microgels dis-
closed herein can be varied to fine tune the permeability and 50 
size of the resulting microgels. 
1. Permeability 
A tunable hydrogel network with selective permeability to 
biomolecules is can be important for cell microencapsulation, 
particularly when the microgels are used for encapsulating 55 
cells. For example, in transplantation applications, antibodies 
and immune cells (relatively large objects) should be pre-
vented from reaching encapsulated cells, while nutrients, sig-
naling molecules, and waste (relatively small molecules) 
should be easily transported across the microgel capsule. 60 
Modulating permeably can also be used to control the release 
kinetics of an encapsulated bioactive agent in drug delivery 
applications. 
For example, analysis of release kinetics detailed in the 
Examples below show that micro gels composed of a 20 kDa 65 
macromer PEG-4MAL polymer release nearly 100% of the 
smaller molecules glucose and insulin. Alternatively, for 
kinetics can be tested using known methods, for example, the 
protein encapsulation and release assays described in the 
Examples below. 
2. Size 
Tunable control of particle size and monodispersity are 
important for many applications of microgels, and the dis-
closed microfluidic platform affords this control over a wide 
range of particle sizes. Typical microencapsulation tech-
niques (e.g. droplet generators using parallel air flow or elec-
trostatic charge) are hindered by the inability to produce 
capsules small enough for adequate nutrient diffusion to 
encapsulated cells, because large void spaces within capsules 
hinder diffusion. An advantageous aspect of the microfluidic 
technology disclosed herein is the capacity for tailoring of 
capsule size to cell type. A wide range of cell or particle sizes 
are able to be encapsulated, from, for example, 300 µm islet 
cell clusters to 10 µm single cells and smaller, with minimal 
void space. This results in more advantageous nutrient and 
therapeutic agent diffusion than similar technologies. 
Additionally, the use of synthetic polymers can provide a 
greater ability to tailor the local environment towards the 
specific needs of the application. An advantage ofthis system 
over alternative methods utilizing synthetic polymers is the 
maintenance of high islet viability and function. Many alter-
native synthetic encapsulation schemes utilize or result in 
components toxic to islets, which consequently limits the 
success of these techniques. 
At least two different parameters, of the disclosed plat-
form, flow rate and channel/nozzle size, can be varied alone, 
or combination to modulate the microgel size and dispersity. 
The Examples below illustrate that using a fixed nozzle 
size of 300 µm nozzle, micro gels with a wide range of sizes, 
ranging from 20 to 400 µm, could be produced on the same 
device by varying modulating the macromer phase flow rate 
between 0 µI/min and 30 µI/min; the oil phase between 5 
µI/min and 100 µI/min; and the crosslinker phase between 10 
µI/min and 400 µI/min. Although several flow regimes pro-
duced microgels with undesirable polydisperse distributions 
(coefficient of variation, CV> 10% ), flow rate combinations 
were identified that produced a range of microgel sizes from 
135-325 µm with monodisperse populations (CV<5%) (see 
FIG. 2A-2E). 
Therefore, the flow rates of one or more of the phases can 
be adjusted to fine tune the size of the microgels that are 
produced. For example, the flow rate of each of the mac-
romere phase, the oil phase, and crosslinker phase in a microf-
luidic device is generally "X" nl/min, wherein "X" is an 
integer between about 100 and about 1,000,000, preferably 
between about 1,000 and about 500,000, more preferably 
between about 1,000 and 50,000, inclusive. The flow rate of 
each of the macromere phase, the oil phase, and crosslinker 
phase in a microfluidic device can also be "X" µI/min, 
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wherein "X" is an integer between about 1 and about 1,000, 
preferably between about 1 and about 500, more preferably 
between about 1 and 50, inclusive. The flow rates can also be 
adjusted as needed to accommodate the selected nozzle size. 
Although a device with fixed geometry is capable of pro-
ducing a wide range of particle sizes, in preferred embodi-
ments, the nozzle size is selected based on the desired size of 
the droplets. In preferred embodiments, droplets are gener-
ated with diameters that are between about 50% and about 
100%, inclusive of the nozzle width to obtain a monodisperse 
population. For example, a 300 µm nozzle was very effective 
for producing monodisperse populations in the range of about 
135 µm to about 325 µm depending on the selected flow rates. 
If monodisperse populations of microgels are required that 
are outside the 135-325 µm range, the microfluidic device 
nozzle can be scaled up or down so that nozzle is roughly 
equal to the desired microgel size. 
In the Examples below, nozzle sizes of 200 µm, 300 µm, 
400 µm, and 600 µm, were tested. The device used for islet 
encapsulation was scaled to have a 600 µm nozzle, and pro-
duced microgels from 300-800 µm in diameter. As a further 
demonstration of the versatility of this platform, human mes-
enchymal stem cells (hMSCs ), were encapsulated in PEG-
4MAL microgels of either 400 µm or 90 µm diameter, func-
tionalized with a cell adhesive RGD peptide. After 
encapsulation, hMSCs encapsulated in both microgel sizes 
exhibited high viability, and hMSCs in 400 µm diameter 
microgels were maintained in suspension culture for 7 days 
with no loss in viability. Generally the nozzle size should 
between about 3 µm and 1,500 µm, or between about 50 µm 
and 1,000 µm, or between about 100 µm and 750 µm. 
10 
of "N" Da, wherein N is any integer between 1,000 and 
200,000. In a particular embodiment, the molecular weight of 
the PEG or derivative thereof is "N" Da, wherein "N" is 
between 1,000 and 100,000, or between about 1,000 and 
50,000. 
Preferably, the polymer is a hydrophilic polymer. Exem-
plary macromers are known in the art. See, for example, U.S. 
Pat. No. 8,017,733, which provides a non-limiting list of 
water-soluble andnon-peptidic polymers including polyalky-
10 lene glycol polymers, polyalkylene oxide homopolymers 
such as polypropylene glycols, polyoxyethylenated polyols, 
copolymers thereof and block copolymers thereof, as well as 
poly(oxyethylated polyol), poly(olefinic alcohol), poly(vi-
nylpyrrolidone ), poly(hydroxypropylmethacrylamide ), poly 
15 (a-hydroxy acid), poly( vinyl alcohol), polyphosphazene, 
polyoxazoline, poly(N-acryloylmorpholine) and copoly-
mers, terpolymers, and mixtures thereof. 
A preferred polymer is ethylene glycol (EG) polymer (i.e., 
polyethylene glycol) (PEG) or a derivative thereof. Deriva-
20 tives of PEG include, but are not limited to, methoxypolyeth-
ylene glycol succinimidyl propionate, methoxypolyethylene 
glycol N-hydroxysuccinimide, methoxypolyethylene glycol 
aldehyde, methoxypolyethylene glycol maleimide, PEG 
derivatives with "click" chemistries functional groups and 
25 multiple-branched polyethylene glycol. 
The precise number of EG or derivative units depends on 
the desire porosity ofthemicrogel, as discussed in more detail 
below. In some embodiments, the molecular weight of the 
PEG or derivative thereof is between about 1 and 200 kDa, or 
30 between about 1 and 100 kDa, or between about 1 and 50 kDa. 
For example, the PEG or derivative thereof can have a 
molecular weight of "N" kDa, wherein N is any integer 
between 1 and 200. 
The PEG or derivative thereof can have a molecular weight 
of "N" Da, wherein N is any integer between 1,000 and 
200,000. In a particular embodiment, the molecular weight of 
the PEG or derivative thereof is "N" Da, wherein "N" is 
between 1,000 and 50,000. 
Droplet sizes can range from less than 10 µm to greater than 
1,000 µm. The droplets can be monodispersed or polydis-
persed. In preferred embodiments, the droplets are monodis-
persed droplets of a size between about 10 µm and 1,000 µm, 35 
inclusive. In some embodiments, the droplets are of a size 
between about 100 µm and 400 µm, inclusive. In some 
embodiments, the droplets are of a size between about 10 µm 
and 20 µm, inclusive, or between about 15 µm and 20 µm, 
inclusive. 
In specific exemplary embodiments, the PEG or derivative 
40 thereof is 10 kDa, 20 kDa, 30 kDa, 40 kDa, or 50 kDa. 
Flexibility in protein encapsulation, as well as the ability to 
simultaneously control therapeutic release kinetics and par-
ticle size, renders this encapsulation platform suitable for a 
wide range of cell and bioactive agent delivery applications. 
In the most preferred embodiments, the polymer is a 
branched or multi-armed macromere with 2 or more "arms". 
In some embodiments, the macromer has between 2-8 arms, 
for example, 2, 3, 4, 6, or 8 arms. Multi-arm PEG, also 
III. Compositions for Making Microgels 
45 referred to as "star" PEG, of various sizes are known in the art 
and commercially available. 
A. Macromer Phase 
In the most preferred embodiments, the polymer can be 
crosslinked by Michael-type addition reaction driven by the 
crosslinker. Therefore, in some embodiments, the polymer or The macromer phase typically includes a polymer or mac-
romer and one or more cargos in an aqueous solution. The 
aqueous solution is typically a physiological buffer, for 
example, water, saline, buffered saline, etc. The buffer can be 
a nucleophilic buffer, such as triethanolamine (TEA). 
1. Polymers 
50 macromer, for example PEG or derivative thereof, is modified 
to include a moiety that can facilitate crosslinking of two or 
more polymers by Michael-type addition. For example, moi-
eties suitable for Michael-type addition include, but are not 
limited to, maleimides, vinyl sulfones, and acrylates. Other 
55 suitable reactive chemistries include N-hydroxysuccinimide, 
succinimidyl propionate, thiol-ene and other "click" chemis-
The marcomer phase includes a polymer or macromer. The 
polymer or macromer is one that can be crosslinked to form a 
microgel in the presence of a suitable crosslinker. Preferably, 
the polymer of the macromer phase is a hydrophilic multi-
armed/branched macromer, as described in more detail 
below. The macromere can be formed from any of the suitable 60 
hydrophilic polymers provided herein or otherwise known in 
the art. In some embodiments, the molecular weight of the 
polymer or macromer is between about 1 and 200 kDa, or 
between about 1 and 100 kDa, or between about 1 and 50 kDa. 
For example, the polymer or macromer can have a molecular 65 
weight of "N" kDa, wherein N is any integer between 1 and 
200. The polymer or macromer can have a molecular weight 
tries. 
In preferred embodiments, the polymer is PEG or deriva-
tive thereof including one or more maleimides. The maleim-
ide( s) are typically linked to the end of the PEG polymer (see, 
for example FIG. 1). Also referred to herein as PEG-MAL, 
various maleimide-linked polyethylene glycol chains are 
known in the art. Such polymers are often used as flexible 
linking molecules to attach proteins to surfaces. The maleim-
ide double bond readily reacts with a thiol group, for example 
the thiol group found on cysteine, to form a stable carbon-
sulfur bond. 
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In the most preferred embodiments, the polymer is a male-
imide-linked branched polyethylene glycol with 2 or more 
"arms". In some embodiments, the PEG, or derivative 
thereof, has between 2-8 arms, for example, 2, 3, 4, 6, or 8 
arms. Multi-arm PEG, also be referred to as "star" PEG, of 
various sizes are known in the art and commercially available. 
In a particular preferred embodiment, the polymer is a four 
arm PEG-MAL (also referred to herein as PEG-4MAL). The 
PEG-4MAL hydrogel system has advantages over other 
hydrogel chemistries, including a well-defined hydrogel 10 
structure, facile and stoichiometric incorporation of bioli-
gands, increased cytocompatibility, improved crosslinking 
efficiency, and tunable reaction rates (Phelps, et al., Advanced 
Materials, 24(1):64-70 (2012)). Additionally, the PEG-
4 MAL macromer exhibits minimal toxicity and inflanmiation 15 
in vivo and is rapidly excreted via the urine (Phelps, et al., 
Biomaterials, 4602-11 (2013)), which indicate the polymers 
are likely to be well tolerated when used for the in vivo 
12 
out over time. For example, in some embodiments, the micro-
gel encapsulates both cell(s) and one or more bioactive 
agents. The bioactive agent can be retained, encapsulated 
with the cells, thereby modulating the cells' microenviron-
ment. 
In some embodiment, the polymer is functionalized with 
one or more bioactive agents prior to crosslinking to form the 
microgel. In this way, small molecules, peptides, proteins, 
and other bioactive agents can be incorporated in the micro-
gel. The active agents can be functionalized in such a way that 
they remain attached to the polymer, or such that they are later 
released from the microgel. For example, in particular 
embodiments the bioactive agent is functionalized in such a 
way that it can be released by a protease or other enzymes in 
vivo when administered to a subject in need thereof. The 
protease can be associated with a disease condition such that 
the bioactive agent is selectively released to treat the disease. 
For example, a therapeutic antibody or protein can be release application disclosed herein. 
2. Cargo 
The macromer phase includes a cargo. The cargo is 
selected based on the desired application. The cargo is, or can 
include, proteins, peptides, amino acids, nucleic acids, car-
bohydrates, lipids, small molecules, or combinations thereof. 
20 by generating micro gels crosslinked by molecules that can be 
cleaved by enzymes, such as cathepsins, metalloproteinases, 
and metalloproteases. In some embodiments, the bioactive 
agent is designed, engineered, functionalized or otherwise 
In some preferred embodiments the cargo is a cell or cells, or 25 
a macromolecule such as a peptide or a protein. 
a. Cells 
modified in include a proteolytic or other enzymatic cleavage 
site for one or more specific proteases or other enzymes. 
In a particular embodiment, the polymer is a PEG-MAL 
such as PEG-4MAL, and the polymer is functionalized by 
reacting a bioactive agent with the maleimide group prior to 
crosslinking. The Examples below illustrate PEG-MAL func-
30 tionalized with RGD peptide. The peptide remained bound to 
the polymer and supported cell adhesion, survival, and func-
The cargo can be a single cell. The cargo can be a group or 
cluster of cells. The cluster or group of cells can be homog-
enous (e.g., all of the same cell type), or heterogenous (e.g., 
two or more different cell types). Suitable cells include, but 
are not limited to differentiated mesenchymal cells, epithelial 
cells, neural cells, endothelial cells, epithelial cells, myo- 35 
blasts, chondrocytes, myoblasts, osteoblasts, osteoclasts, 
bone marrow cells, adult stem cells, embryonic stem cells, 
umbilical cord blood cells, fibroblasts, or a combination 
thereof. In some embodiments, the cells are autologous or 
allogeneic cells. The autologous cells may be those naturally 40 
occurring in the donor or cells modified ex vivo. For example, 
ti on. 
Exemplary bioactive agents include tumor antigens, CD4+ 
T-cell epitopes, cytokines, chemotherapeutic agents, radio-
nuclides, small molecule signal transduction inhibitors, pho-
tothermal antennas, immunologic danger signaling mol-
ecules, other immunotherapeutics, enzymes, antibiotics, 
antivirals, anti-parasites (helminths, protozoans), growth fac-
in some embodiments, the cells have been recombinantly 
modified to contain one or more exogenous nucleic acids 
encoding desired protein products. In some embodiments, the 
cells are stem cells isolate from a donor and expanded and/or 45 
differentiated ex vivo prior to encapsulation. 
tors, growth inhibitors, hormones, hormone antagonists, anti-
bodies and bioactive fragments thereof (including human-
ized, single chain, and chimeric antibodies), antigen and 
vaccine formulations (including adjuvants ), peptide drugs, 
anti-inflammatories, immunomodulators (including ligands 
that bind to Toll-Like Receptors (including but not limited to 
CpG oligonucleotides ), nutraceuticals such as vitamins, and 
In a particular embodiment, the cells are human pancreatic 
islets, for example, alpha cells, beta cells, delta cells, PP cells 
(gamma cells), epsilon cells, or any combination thereof. 
oligonucleotide drugs (including DNA, RNAs, antisense, 
aptamers, small interfering RNAs, ribozymes, external guide 
sequences for ribonuclease P, and triplex forming agents). 
In another particular embodiment, the cells are stem cells, 50 
for example mesenchymal stem cells (MSCs), bone marrow-
derived stem cells, embryonic stem cells or induced pluripo-
tent stem cells (iPSCs ). 
Bioactive agents can be diagnostic agents, for example, 
paramagnetic molecules, fluorescent compounds, magnetic 
molecules, andradionuclides, x-ray imaging agents, and con-
trast agents. 
b. Bioactive Agents 
In some embodiments, the cargo is one or more bioactive 
agent. The bioactive agents can small molecule active agents 
or biomacromolecules, such as proteins, polypeptides, or 
nucleic acids. Suitable small molecule active agents include 
organic and organometallic compounds. The small molecule 
active agents can be a hydrophilic, hydrophobic, or 
amphiphilic compound. The bioactive agent can be encapsu-
lated within the micro gel. The microgel can be porous enough 
to allow the bioactive agent to diffusion out to the microgel 
over time. Alternatively, in some embodiments, the micro gel 
is not porous enough to allow the bioactive agent to diffuse 
Bioactive agents can be immunomodulatory such as cytok-
55 ines, xanthines, interleukins such as interleukin-2 and -3, 
interferons including interferon-alpha, -beta and -gamma, 
oligodeoxynucleotides, glucans, growth factors (e.g., TNF, 
CSF, GM-CSF, G-CSF, bFGF(FGF-1), aFGF(FGF-2), EGF 
(epidermal growth factor), PDGF (platelet-derived growth 
60 factor), IGF (insulin-like growth factor), TGF-~1through3, 
including the TGF-~ superfamily (BMPs, GDF-5, ADMP-1 
and dpp)), hormones such as estrogens (diethylstilbestrol, 
estradiol), androgens (testosterone, HALOTESTIN® (flu-
oxymesterone)), progestins (MEGACE® (megestrol 
65 acetate), PROVERA® (medroxyprogesterone acetate)), and 
corticosteroids (prednisone, dexamethasone, hydrocorti-
sone). 
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In some embodiments, the bioactive agent is a hormone, 
such as, insulin, growth hormone-releasing factor and calci-
tonin. The hormone can be non-peptide hormone. 
The cargo can also be antigens and/or adjuvants (i.e., mol-
ecules enhancing an immune response), or other peptide, 5 
protein, or DNA based vaccines components. 
In a preferred embodiment, the cargo includes one or more 
growth factors. Growth factors include, but are not limited to 
adrenomedullin (AM), angiopoietin (Ang), autocrine motil-
ity factor, bone morphogenetic proteins (BMPs), brain-de- 10 
rived neurotrophic factor (BDNF), epidermal growth factor 
(EGF), erythropoietin (EPO), fibroblast growth factor (FGF), 
glial cell line-derived neurotrophic factor (GDNF), granulo-
cyte colony-stimulating factor (G-CSF), granulocyte mac-
rophage colony-stimulating factor (GM-CSF), growth differ- 15 
entiation factor-9 (GDF9), healing factor, hepatocyte growth 
factor (HGF), hepatoma-derived growth factor (HDGF), 
insulin-like growth factor (IGF), keratinocyte growth factor 
(KGF), migration-stimulating factor, myostatin (GDF-8), 
nerve growth factor (NGF) and other neurotrophins, platelet- 20 
derived growth factor (PDGF), thrombopoietin (TPO), trans-
forming growth factor alpha(TGF-a), transforming growth 
factor beta(TGF-~), tumor necrosis factor-alpha(TNF-a), 
vascular endothelial growth factor (VEGF), Wnt and Wnt 
Signaling Pathway molecules, placental growth factor (PGF), 25 
[(Foetal Bovine Somatotrophin)] (FBS), IL-I-Cofactor for 
IL-3 and IL-6, IL-2, IL-3, IL-4, IL-5, IL-6, and IL-7. 
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crosslinker-in-oil emulsion. In the Examples below, the 
crosslinker phase is composed of the continuous phase (oil 
phase) with an emulsion of the crosslinker. However, it will be 
appreciated that the oil and surfactant components and/or 
percentages of the crosslinker phase need not be exactly the 
same as the components and/or percentages of the oil phase. 
More specifically, in some embodiments, the oil phase and 
crosslinker phase are composed of the same oil and in the 
same surfactant. In some embodiments, the oil phase and 
crosslinker phase are composed of the same oil and different 
surfactants. In some embodiments, the oil phase and 
crosslinker phase are composed of different oils and the same 
surfactant. In some embodiments, the oil phase and 
crosslinker phase are composed of different oils and different 
surfactants. The percent of the surfactant in the oil and 
crosslinker phases can be same, or can be different. 
The crosslinker is ultimately selected based on the polymer 
being used to form the microgel. Preferably the crosslinker is 
cytocompatibe and is not toxic to cells. In the most preferred 
embodiments, the crosslinker cause little or no cell death, 
and/or little or no cell stress when cells are encapsulated 
according to the disclosed platform. 
In the most preferred embodiment, the polymer includes 
one or more moieties that enable its crosslinking to other 
polymer molecules via a Michael-type addition reaction 
between the polymer/macromer and crosslinker. In a particu-
lar embodiment, the polymer/macromer includes one or more 
maleimide groups, the crosslinker includes one or more thi-
In a preferred embodiment, the cargo includes one or more 
chemokines Chemokines including, but not limited to CC 
chemokines, CXC chemokines, C chemokines, and CXC3 
chemokines CC chemokines include: CCLI, CCL2, CCL3, 
CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/CCLIO, CCLII, 
CCLl2, CCL13, CCLl4, CCL15, CCL16, CCL17, CCL18, 
CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, 
CCL26, CCL27, and CCL28. CXC chemokines include: 
30 ols, and the Michael-type addition reaction is between the 
maleimide groups on the polymer/macromer and thiols on the 
crosslinker. Fast reaction kinetics renders this hydrogel 
advantageous for microfluidic encapsulation, allowing for 
short residence time on chip, and minimizing cell stress. This 
CXCLI, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, 
CXCL7, CXCL8, CXCL9, CXCLIO, CXCLll, CXCLl2, 
CXCL13, CXCLl4, CXCL15, CXCL16, and CXCLl7. C 
chemokines include: XCLI and XCL2. CXC3 chemokines 
include CX3CL1. 
35 Michael-type addition reaction requires no free radicals and 
is cytocompatible (Phelps, et al., Advanced Materials, 24(1 ): 
64-70 (2012)). The Examples below show that a microencap-
sulation process carried out in this way does not affect the 
viability or function of human pancreatic islets and mesen-
40 chymal stem cells (hMSCs ). 
Exemplary crosslinkers include dithiothreitol (DTT) and 
biodegradable crosslinkers, for example, cysteine-containing 
peptides such 
In some embodiments, the agents are those factors, pro-
teinaceous or otherwise, which are found to play a role in the 
induction or conduction of growth of bone, ligaments, carti-
lage or other tissues associated with bone or joints, such as for 
example, BMP and bFGF. 
B. Shielding/Oil Phase 
45 
50 
The oil phase (also referred to herein as the shielding 
phase) is composed of oil and surfactant. In preferred 
embodiments, the oil is mineral oil. Other suitable oils 
include, but are not limited to, propylene glycol, glycerol, and 
vegetable oil. In a preferred embodiment, the surfactant is 
SPAN® 80 (e.g., 2%, as exemplified in the Examples below). 
Other suitable surfactants are known in the art. A non-limiting 
list of preferred surfactants includes, TWEEN®-80, polysor-
bate-20, polysorbate-80, and ammonium lauryl sulfate, 55 
among others. The surfactant concentration typically ranges 
from about 0.1 % to about 20%. 
C. Crosslinker Phase 
Biodegradable crosslinkers Peptide sequence Mw 
GPQ (W) (SEQ ID NO, 2) GCRDGPQGIWGQDRCG 1704.88 
(SEQ ID NO, 4) 
VPM GCRDVPMSMRGGDRCG 1696.99 
(SEQ ID NO, 5) 
GPQ (A) (SEQ ID NO, 3) GCRDGPQGIAGQDRCG 1589.74 
(SEQ ID NO, 6) 
which are examplifed in the Examples below and described in 
Phelps, et al., Biomaterials, 34(19):4602-4611 (2013). Such 
peptide typically include at least one, preferably two or more 
cysteines. In addition to DTT and cysteine( s )-containing pep-
tides, other molecules containing free thiols, including func-The crosslinker phase is generally constitutionally similar 
to the oil phase and further including a crosslinker capable of 
crosslinking the polymer in the macromer phase to form a 
microgel. As droplets containing cargo are formed, diffusion 
of the crosslinker from the crosslinker phase crosslinks the 
hydrogel network, forming a semipermeable capsule. While 
some crosslinkers can be dissolved directly in a continuous 
phase (oil phase) to form the crosslinker phase, hydrophilic 
chemicals are first dissolved in aqueous phase to form a 
60 tionalized carbohydrates and nucleic acids, can be used. 
In some embodiments, the crosslinker is designed to be 
degraded in the presence of a protease or another enzyme or 
molecule. Such embodiments can be designed to fine tune the 
release of the cargo by degrading the microgel. For example, 
65 in some embodiments, the crosslinker is designed to be 
degraded over time in vivo in the presence of a protease or 
another enzyme or molecule that is expressed in vivo. In other 
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embodiment, protease or another enzyme or molecule can be 
provided (for example administered to the subject) to facili-
tate release of the cargo. In some embodiments, expression or 
presence of the protease, or other enzyme or molecule is 
correlated with a disease or disorder so that cargo is released 
preferential under disease conditions or in close proximity to 
a diseased area. In a particular embodiment, the crosslinker is 
16 
methods disclosure herein to be selective permeability, for 
example, prevented antibodies and immune cells (relatively 
large objects) from reaching encapsulated cells, while nutri-
ents, signaling molecules, and waste (relatively small mol-
ecules) can be easily transported across the micro gel capsule. 
In this way the transplanted cells can carry out their purpose 
will evading detection and rejection by the host's immune 
system. 
The encapsulated cells can be implanted or injected 
10 directly into the site as needed. Microgel droplets having a 
diameter greater than 250 µm may tend to block needles used 
to deliver the droplets to a host. Accordingly, the disclosed 
microcapsules having a diameter of less than about 250 µm, 
typically less than about 200 µm can be delivered to a host via 
a peptide that includes one or more cysteines that can 
crosslink macromers by a Michael-type addition reaction, but 
also includes a proteolytic site for one or more enzymes. In 
the most preferred embodiments, the peptide includes a 
cleavage site and least one cysteine on each side of the cleav-
age site. Examples include, but are not limited to, the biode-
gradable crosslinkers discussed above, and in the Examples 
below, which can be degraded by a wide range of proteases 
including collagenase I (e.g., cysteine-flanked protease-de-
gradable peptide GCRDVPMStMRGGDRCG (SEQ ID 
N0:5) (VPM), where 1 indicates the cleavage point). Exem-
plary peptide crosslinkers include, but are not limited to, 
peptides including the amino acids of SEQ ID NOS:4, 5, or 6, 20 
or a variant thereof with at least 70%, 80%, 85%, 90%, 95%, 
15 injection with a standard surgical needle, for example a 14 
gauge or 18 gauge needle, in an amount sufficient to treat the 
host. Large micro gel droplets may be delivered using a larger 
needle or an alternative approach, for example, surgical 
implantation. 
The encapsulated cells can be cells that secrete a polypep-
tide needed to treat the pathology, for example insulin to 
control glycemia. It will be apparent to those skilled in the art 
that the quantity of micro gel droplets transplanted depends on 
the ability of the microgel droplets to provide function in 
or more sequence identity to SEQ ID N0:4, 5, or 6, and which 
preferably includes two cysteines, and can be cleaved by one 
or more proteases. 
As discussed in more detail above and exemplified below, 
this system is also easily modified with thiol-containing mol-
ecules, including cysteine-containing adhesive ligands and 
growth factors and other bioactive agents, due to the high 
specificity of the maleimide groups for thiols at physiological 
pH. 
In the most preferred embodiments, the crosslinking is not 
based on ultraviolet (UV) initiated photopolymerization and/ 
or free radical generation. 
IV. Methods of Using Microgels 
The micro gels disclosed herein can be utilized in a number 
of in vivo applications. Exemplary applications include cell 
transplantation and drug delivery. 
A. Transplantation 
Encapsulated cells produced according to the present dis-
closure can be transplanted into subjects as a treatment of 
pathologies including, but not limited to tissue damage, 
ischemia, insulin-dependent diabetes, heart attack, nerve 
damage, brain damage, bone damage, or cartilage repair. 
Such transplantation may be into the peritoneal cavity of the 
subject, or directly into a pathology site. 
The methods can be used to generate cells which may be 
useful in the treatment of a variety of diseases and disorders, 
including, but not limited to, neurodegenerative diseases such 
as Parkinson's, Alzheimer disease, and multiple sclerosis. 
The methods are also useful for organ regeneration, and for 
restoration or supplementation of the immune system. For 
example, cells at different stages of differentiation such as iPS 
cells, hematopoietic stem cells, multipotent cells or uni potent 
cells such as precursor cells, for example, epithelial precursor 
cells, and others can be administered intravenously or by local 
surgery to treat a disease or disorder. In some embodiments, 
the droplets are designed to direct cell behavior and fate of 
encapsulated cells, cell adjacent to the site of implantation, or 
a combination thereof. The methods can be used in combina-
tion with other conventional methods, such as a prescription 
medication regime, surgery, hormone therapy, chemotherapy 
and/or radiotherapy. 
In some embodiments, the microgel is designed to be 
immunoisolated from the host tissue. The permeability or 
porosity of microgel can be fined tuned according to the 
25 vivo. One skilled in the art will be able to determine suitable 
transplantation quantities of microgel droplets, using tech-
niques as are known in the art. 
A further embodiment provides a method for treating a host 
by delivering encapsulated cells to the host produced accord-
30 ing to the present disclosure. For example, the encapsulated 
cells can produce cartilage or cartilage components, or 
secrete insulin in the host. 
A further embodiment provides a method for repairing 
tissue in a host by administering encapsulated cells produced 
35 according the present disclosure, wherein the encapsulated 
cells produce tissue or tissue components in the host. 
B. Drug Delivery 
In some embodiments, the micro gel droplets do not contain 
cells. In such embodiments the microgel droplets are typi-
40 cally loaded with or functionalized with a bioactive agent 
such as those discussed above. The microgel droplets can be 
used to deliver an effective amount of one or more therapeu-
tic, diagnostic, and/or prophylactic agents to an individual in 
need of such treatment. The amount of agent to be adminis-
45 tered can be readily determine by the prescribing physician 
and is dependent on the age and weight of the patient and the 
disease or disorder to be treated. 
The microgel droplets are useful in drug delivery (as used 
herein "drug" includes therapeutic, nutritional, diagnostic 
50 and prophylactic agents), whether injected or surgically 
administered. The microgel droplets are typically adminis-
tered in an aqueous suspension (in water, saline, buffered 
saline, etc.). 
As discussed herein, microgel droplets can be used to as 
55 delivery vehicles for a number of active agent cargos includ-
ing small molecules, nucleic acids, proteins, and other bioac-
tive agents. The active agent or agents can be encapsulated 
within, dispersed within, and/or associated with the surface of 
the microgel. In some embodiments, the microgel packages 
60 two, three, four, or more different active agents for simulta-
neous delivery. 
The release kinetics of the cargo can be modulated by 
varying the permeability of the microgel as discussed in more 
detail above. Therefore, depending on the size of the agent 
65 and the permeability of the microgel, the microgel formula-
tion can be designed for immediate release (e.g., burst 
release), or slow or extended release over time. 
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The active agent-loaded microgel droplets can be used to 
treat a variety of diseases and conditions, for example, cancer 
and infectious diseases. The compositions can be adminis-
tered to the subject therapeutically or prophylactically. 
C. Pharmaceutical Compositions 
Pharmaceutical compositions including microgel droplets 
are provided. Pharmaceutical compositions can be for admin-
istration by transplantation, parenteral (intramuscular, intra-
peritoneal, intravenous (IV) or subcutaneous) injection, or 10 
another suitable means. Compositions can be formulated in 
dosage forms appropriate for each route of administration. 
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EXAMPLES 
Example 1 
Design and Testing of a Microfluidic Strategy for 
Encapsulating Cells and Other Biological Agents 
Materials and Methods 
Microfluidic Device Preparation 
PDMS microfluidic flow focusing devices were cast using 
soft lithography from silicon and SUS masters that were 
fabricated by the Stanford Microfluidics Foundry. Devices 
with 300 µm nozzles were bonded directly to glass slides after 
treatment with air plasma. 600 µm nozzle devices were manu-In some embodiments, the compositions are administered 
systemically, for example, by intravenous or intraperitoneal 
administration, in an amount effective for delivery of the 
compositions to targeted cells, tissue, etc. 
15 factured by first bonding mirror-image PDMS charmels, each 
with 300 µm depth, together to create a charmel with 600 µm 
depth. 
In certain embodiments, the compositions are adminis-
tered locally, for example by transplantation or injection 
directly into a site to be treated. In some embodiments, the 20 
compositions are injected or otherwise administered directly 
diseased or disorder tissue. Typically, local injection causes 
PEG-4MAL Microgel Formation and Particle Encapsula-
tion 
Flow-focusing microfluidic geometry was utilized to form 
polymer droplets. Both shielding and crosslinker phases con-
sisted oflight mineral oil (Sigma) with 2% SPANSO (Sigma). 
The crosslinker phase also contained an emulsion, at a ratio of 
1: 15, of 20 mg/mL dithiothreitol (DTT) (Sigma) in PBS. A 
an increased localized concentration of the compositions 
which is greater than that which can be achieved by systemic 
administration. In some embodiments, the compositions are 
delivered locally to the appropriate cells by using a catheter or 
syringe. Other means of delivering such compositions locally 
to cells and tissue include using infusion pumps (for example, 
fromAlza Corporation, Palo Alto, Calif.) or incorporating the 
compositions into implants. 
The microgels can be formulated in a physiologically 
acceptable carrier or vehicle, and injected or otherwise deliv-
ered into a tissue or fluid surrounding the target area. 
25 co-flowing shielding phase protected the macromer solu-
tion-a 5% PEG-4MAL (10 kDa or 20 kDa, Laysan Bio) 
solution containing molecules or cells to be encapsulated-
from the crosslinker phase until droplets of the macromer 
solution were formed. DTT rapidly diffused into macromer 
30 droplets, forming crosslinked microgels. To functionalize 
hydrogel with GRGDSPC (SEQ ID NO:l) ('RGD', 
AAPPTec ), macromer was reacted for 20 minutes before 
encapsulation with 2.0 mM RGD in buffer solution contain-
ing 4 mM triethanolamine (Sigma). After formation, micro-
35 gels were washed 5 times by centrifugation to remove mineral 
oil and excess DTT. 
As further studies are conducted, information will emerge 
regarding appropriate dosage levels for treatment of various 
conditions in various patients, and the ordinary skilled 
worker, considering the therapeutic context, age, and general 
health of the recipient, will be able to ascertain proper dosing. 
40 
The selected dosage depends upon the desired therapeutic 
effect, on the route of administration, and on the duration of 
the treatment desired. 
Results 
FIG. 1 illustrates a platform and strategy to produce cell-
and cell aggregate-laden synthetic PEG-4MAL-basedmicro-
gels, functionalized with cell adhesive peptides, by producing 
droplets using a flow focusing microfluidic device and sub-
sequently covalently crosslinking the droplets with the small 
molecule dithiothreitol (DTT). Three independent flows of 
(1) mineral oil containing SPANSO (a surfactant), (2) a In a preferred embodiment the nanolipogels are in a phar-
maceutical composition including an aqueous solution suit-
able for parenteral delivery. The formulation can be in the 
form of a suspension or emulsion. In general, pharmaceutical 
compositions are provided including effective amounts of 
cargo, and optionally include pharmaceutically acceptable 
diluents, preservatives, solubilizers, emulsifiers, adjuvants 
and/or carriers. Such compositions can include diluents ster-
ile water, buffered saline of various buffer content (e.g., Tris-
HCl, acetate, phosphate), pH and ionic strength; and option-
ally, additives such as detergents and solubilizing agents (e.g., 
TWEEN® 20, TWEEN® 80 also referred to as polysorbate 
45 crosslinker phase containing mineral oil and SPANSO with an 
emulsion of aqueous DTT solution, and (3) PEG-4MAL mac-
romer in aqueous physiological buffer were pumped into the 
microfluidic chip using syringe pumps. As the macromer 
phase approached the flow-focusing nozzle, a coflowing con-
50 tinuous phase of oil shielded the macromer from contact with 
the crosslinker-laden oil phase. Because crosslinker could not 
reach the macromer before flow instability occurred, mono-
disperse, spherical droplets were formed. The crosslinker 
then rapidly diffused into droplets, covalently crosslinking 
55 the PEG-4MAL macromer into the microgel network via 
Michael-type addition reaction of the maleimide groups on 
the macromer and thiols on the crosslinker. The PEG-4MAL 
hydro gel platform used for this system is easily modified with 
20 or 80), anti-oxidants (e.g., ascorbic acid, sodium met-
abisulfite ), and preservatives (e.g., Thimersol, benzyl alco-
hol) and bulking substances (e.g., lactose, marmitol). 
Examples of non-aqueous solvents or vehicles are propylene 60 
glycol, polyethylene glycol, vegetable oils, such as olive oil 
and com oil, gelatin, and injectable organic esters such as 
ethyl oleate. Optional components of a pharmaceutical com-
position can be selected based on the composition of the 
microgel and its cargo. For example, ifthe cargo is cells, the 65 
additional agents in the pharmaceutical composition should 
thiol-containing molecules, including cysteine-containing 
adhesive ligands and growth factors, due to the high specific-
ity of the maleimide groups for thiols at physiological pH. 
This Michael-type addition reaction requires no free radi-
cals and is cytocompatible (Phelps, et al., Advanced Materi-
als, 24(1):64-70 (2012)). Furthermore, fast reaction kinetics 
render this hydrogel ideal for microfluidic encapsulation, 
allowing for short residence time on chip, and minimizing 
be compatible with cell viability. cell stress. 
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Example 2 
Size and Dispersity of the Microgels are Tunable 
Materials and Methods 
Microgel Size Control 
20 
To characterize the relationship between microgel size and 
the various macromer solution and continuous phase flow 
rates, hydrogel droplets were generated using computer-con-
trolled syringe pumps, and were measured while still in the 
microfluidic chip. Harvard Apparatus Elite syringe pumps 
were computer controlled using FlowControl software to 
pump inlet solutions at various flow rates. Video was recorded 
during droplet generation using a Hammamatsu ORCA-ERA 
1394 camera connected to a Nikon TE300 microscope. Drop- 15 
let diameter was measured using ImageJ analysis software. 
The coefficient of variation (CV) was calculated for each flow 
rate combination by dividing the standard deviation of the 
sample by its mean. At least 30 microgels were measured for 
each flow rate combination. 
supernatant alone, as well as of supernatant containing well-
mixed, protein-laden microgels. These samples were placed 
in a 96 well plate, and their fluorescent intensity was mea-
sured using a Perkin Elmer HTS 7000 plate reader. To gen-
erate release curves, supernatant samples were collected over 
the course of3 days, and their fluorescent intensity was mea-
sured. Protein release was normalized by setting fluorescent 
intensity of the supernatant alone correspond to 0% protein 
released, and fluorescent intensity of the buffer/microgel 
10 
mixture correspond to 100% protein released. This data was 
plotted using GraphPad Prism, and exponential best fit curves 
were calculated from normalized data. 
Results 
A tunable hydro gel network with selective permeability to 
biomolecules is important for cell microencapsulation, 
because antibodies and immune cells (relatively large 
objects) must be prevented from reaching encapsulated cells, 
while nutrients, signaling molecules, and waste (relatively 
20 small molecules) should be easily transported across the 
microgel capsule. Therefore, the suitability of microgels for 
biomolecule release and cell encapsulation was tested by 
measuring their permeability to relevant molecules of various 
sizes that were labeled with fluorescent tags. These molecules 
Results 
Precise control of particle size and monodispersity are 
critical for many applications of microgels, and the microf-
luidic platform affords this control over a wide range of 
particle sizes. The macromer solution and continuous phase 
flow rates for a device with a 300 µm nozzle, were varied and 
corresponding droplet size for each flow rate was measured 
(FIG. 2A-2E). No cells were encapsulated in this application. 
Micro gels with a wide range of sizes, ranging from 20 to 400 
µm, could be produced on the same device; however, several 
flow regimes produced microgels with undesirable polydis-
perse distributions (coefficient of variation, CV> 10% ). 
Importantly, flow rate combinations were identified that 
produced a range of microgel sizes from 135-325 µm with 
monodisperse populations (CV<5%). An example of one of 
these flow rates is shown in FIGS. 2A-2E, along with several 
other representative flow regimes, including one regime that 
does not produce droplets and one that produces a very poly-
disperse (CV=22%) microgel population. Although a device 
with fixed geometry is capable of producing a wide range of 
particle sizes, preferably droplets should be generated with 
diameters that are 50-100% of the nozzle width to obtain a 
monodisperse population. Even if polydisperse populations 
are acceptable, device throughout is limited, because no drop-
lets were formed for any PEG-4MAL macromer flow rates 
exceeding 50 µL min-1. If monodisperse populations of 
microgels are required that are outside the 135-325 µm range, 
the microfluidic device nozzle can be scaled up or down so 
that nozzle is roughly equal to the desired microgel size. 
Example 3 
Permeability of the Microgels is Tunable 
Materials and Methods 
Protein Encapsulation and Release 
AlexaFluor488-labeled IgG (goat anti-rabbit IgG, Life 
Technologies), bovine serum albumin-AlexaFluor488 conju-
gate (Life Technologies), 2-NBDglucose (Life Technologies) 
25 were encapsulated within microgels generated from a 20 kDa 
PEG-4MAL macromer, and the rate of their release into 
buffer was used as a metric of permeability (FIG. 3A). 
2-NBD-glucose (342 Da) was rapidly released from the 
gels, fully equilibrating concentration with the buffer by the 
30 first fluorescence measurement, 5 minutes after swelling. 
Similarly, insulin-AlexaFluor488 (5.8 kDa) was rapidly 
released from the microgels upon swelling, indicating that 
relevant functional molecules diffuse quickly through the 
35 microgel. 
In contrast, encapsulated IgG-AF488 (-160 kDa) was 
released from the micro gels at a slow rate, indicating that the 
microgel capsules are capable of preventing transport and 
binding of antibodies to encapsulated cells. Release kinetics 
40 for BSA (66.5 kDa) fell between IgG and insulin, indicating 
that physical molecular entanglement due to the network 
structure is the determining factor for permeability in our 
hydro gel network. These results show nearly 100% release 
for the smaller molecules glucose and insulin. For the larger 
45 proteins BSA and IgG, the release did not reach 50% of the 
incorporated amount because these larger molecules remain 
trapped within the tight network structure of the PEG hydro-
gel. 
These results for reduced transport and entrapment oflgG 
50 support the use of these materials for immuno-encapsulation 
applications. As a demonstration of the ability to tune net-
work structure for protein release applications, IgG was 
encapsulated in microgels made with PEG macromers of 
55 
different (10 kDa vs. 20 kDa) molecular weights (FIG. 3B). 
The tighter network mesh of the micro gels based on 10 kDa 
macromers slowed the release oflgG compared to microgels 
made with 20 kDa macromer. 
or insulin (Sigma) tagged withAlexaFluor488 was dissolved 60 
in a 5% PEG-4MAL (10 kDa or 20 kDa) solution before being 
microencapsulated by macromere droplet gelation. To pre-
vent proteins from being crosslinked by the macromer, thiols 
were capped using aminoethylate reagent (Thermo Scien-
tific) according to product instructions. Particles were washed 65 
and resuspended in PBS and divided into 5 replicates con-
taining 2 mL total volume. 50 µL samples were taken of 
Because altering macromer size results in drastic changes 
in release kinetics, it is believed that other parameters that 
influence network structure as related to the hydrogel corre-
lation length, such as polymer weight % and crosslinking 
density, can be systematically varied to obtain desired release 
kinetics. Flexibility in protein encapsulation, as well as the 
ability to simultaneously control therapeutic release kinetics 
and particle size, indicate that this encapsulation platform is 
useful for a wide range of protein delivery applications. 
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Example 4 
Micro gels can Encapsulate Clusters of Cells 
Materials and Methods 
Human MSC Encapsulation and Viability Assay 
Passage 3 hMSCs (Texas A&M Health Science Center 
College of Medicine) were trypsinized and washed 3 times 
with PBS before being suspended in RGD-functionalized 
macromer solution (5% wt macromer) at a concentration of 
5xl 06 cells/mL. Generation and subsequent gelation of cell-
laden macromere solution droplets, using a microfluidic 
device with a 300 µm nozzle, resulted in microencapsulated 
hMSCs. These cells were maintained under static culture 
conditions in chemically defined MSC media (Lonza) for 7 
days, with media changes every 2 days. On days 1, 2, 3, 4, and 
7, microencapsulated cells were removed from culture, 
stained with CalceinAM and TOT0-3 iodide (Life Technolo-
gies) for 15 minutes, washed, and resuspended in fresh media. 
At least 200 cells were imaged each day using a Nikon 
Eclipse Ti microscope, and their viabilities were assessed 
based on fluorescent signal. AN OVA analysis was performed 
using GraphPad Prism software. The percent viability was 
calculated by taking the ratio oflive cells to total cells. Viabil-
ity data was plotted using GraphPad Prism. AN OVA analysis 
between the groups found no significant difference in viabil-
ity, and a student's t-test between days 1 and 7 also found no 
significant difference in viability. 
Human Islet Encapsulation and In Vitro 
Characterization 
Human pancreatic islets (PRODO Laboratories and the 
Integrated Islet Distribution Program) were suspended at a 
concentration of 2x 104 IEQ/mL in culture media containing 
5% (w/v) macromer. A microfluidic device with a 600 µm 
nozzle was used for droplet generation and subsequent 
crosslinking of the macromer solution, resulting in microen-
capsulated islets. After microencapsulation, islets were 
washed 5 times with media (PRO DO labs PIM(S)), placed in 
fresh media, and allowed to recover overnight. On days 1, 2, 
5, and 8 after encapsulation, islets were stained with Calcein 
AM and TOT0-3 iodide (Life Technologies) for 15 minutes, 
washed, and resuspended in fresh media. At least 74 islets 
were imaged each day using a Nikon Eclipse Ti microscope, 
and their viabilities were assessed based on fluorescent sig-
nal. For each islet, dead cell area to total islet area was com-
puted, and this fraction was subtracted from 100% to obtain 
percent viability. ANOVA analysis was performed using 
GraphPad Prism software, and no significant difference in 
viability was found. 
On day 1 following encapsulation, a glucose-stimulated 
insulin secretion assay was performed. Islets were washed 
and were equilibrated using 1.67 mM glucose in Hanks Buff-
ered Salt Solution for 30 minutes. Two groups, containing 5 
replicates of approximately 10 islets each, were collected 
from both microencapsulated and bare islets. One group from 
each treatment was incubated with high (16.7 mM) glucose 
HBSS, and the other group was incubated with low (1.67 
mM) glucose HBSS for one hour. Supernatant from each 
sample was collected, and insulin content was quantified 
using human insulin ELISA (Sigma). DNA from each sample 
was then quantified using a Quant-iT PicoGreen kit (Invitro-
gen). Insulin secretion was normalized to DNA content for 
each well. The Stimulation Index for each replicate was cal-
22 
culated by taking the ratio of normalized high glucose insulin 
secretion to normalized low glucose insulin secretion (n=5). 
Groups were compared using a student's t-test in GraphPad 
Prism. Human islets and MSCs were obtained by third party 
distributors, and consent was provided by donors or next of 
kin. 
Results 
Having shown the ability to exclude high molecular weight 
proteins such as IgG with minimal impact on the transport of 
10 critical molecules such as glucose and insulin, cell encapsu-
lation applications of this microgel system were examined 
using clinically relevant cell types. Human pancreatic islets 
were encapsulated with high efficiency (>99% of islets 
loaded into microfluidic device were encapsulated, and 80% 
15 of micro gels produced contain at least one islet), in micro gels 
made from PEG-4MAL, a polymer that has been shown to 
support islet engraftment and function (Phelps, et al., Bio ma-
terials, 4602-11 (2013)). 
Encapsulated islets were maintained in culture for 8 days 
20 with no decrease in viability (FIG. 3C-3 D ), demonstrating the 
capacity of this synthetic hydro gel network to support high 
viability of these sensitive human cells. This result also shows 
that any potentially cytotoxic effects of hydrogel precursor 
constituents (e.g., DTT) prior to network formation are miti-
25 gated by the short residence time of cells in crosslinker emul-
s10n. 
The device used for islet encapsulation was scaled to have 
a 600 µm nozzle, and produced microgels from 300-800 µm 
in diameter. As a further demonstration of the versatility of 
30 this platform, human mesenchymal stem cells (hMSCs ), cur-
rently under investigation for various biomedical applications 
due to their regenerative and immunomodulatory properties, 
were encapsulated in PEG-4MAL microgels of either 400 µm 
or 90 µm diameter. These microgels were precisely function-
35 alized with a cell adhesive RGD peptide (2.0 mM) by simply 
reacting maleimide groups in the macromer with this peptide 
prior to cell encapsulation and hydrogel crosslinking. This 
RGD peptide supports cell adhesion, survival and function 
when incorporated into the PEG-4MAL network (Phelps, et 
40 al., Advanced Materials, 24(1 ):64-70 (2012)). After encapsu-
lation, hMSCs encapsulated in both microgel sizes exhibited 
high viability (FIG. 3E), and hMSCs in 400 µm diameter 
microgels were maintained in suspension culture for 7 days 
with no loss in viability (FIG. 3F). Therefore, controlled 
45 presentation of adhesive peptides to cells encapsulated using 
a cytocompatible crosslinking reaction provides an environ-
ment amenable to long-term cell viability. Such a microenvi-
ronment presenting defined bioactive peptides may be suit-
able not only for cell encapsulation and delivery (Ranganath, 
50 et al., Cell Stem Cell, 10(3):244-58 (2012)), but also for 
directing stem cell behavior and fate (Lutolf, et al., Nature, 
462(7272):433-41 (2009), Lienemann, et al., Advanced 
Healthcare Materials, 2(2):292-6 (2013)).Additionally, con-
trol of micro gel size facilitates optimization for cell delivery 
55 applications. 
An important consideration in the engineering of micro-
gels for cell encapsulation is that key cell functions are not 
negatively impacted following encapsulation. To this end, a 
glucose-stimulated insulin secretion (GSIS) assay was car-
60 ried out to evaluate the function of encapsulated human islets. 
Bare or encapsulated islets were challenged with either 1.67 
mM or 16.7 mM glucose for 30 minutes, and the normalized 
insulin content from each group was assayed using ELISA. 
The stimulation index (SI), or ratio of normalized insulin 
65 secreted in high glucose group to that of low glucose group, 
was calculated for both bare and encapsulated islets. No sig-
nificant difference was found between the groups (FIG. 3F), 
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demonstrating that microfluidic-based encapsulation in PEG-
4MAL has no deleterious effects on human islet function or 
viability, and that mass transfer of molecules relevant to islet 
function is not significantly affected by microencapsulation. 
24 
tion. Smaller capsules generated with the 400 µm device 
exhibited preferred diffusion kinetics for insulin secretion 
from islets encapsulated within the PEG hydrogel. Glucose-
stimulated insulin secretion from PEG encapsulated islets is 
illustrated in FIG. lE, where encapsulated islets perform 
comparably to unmodified islets. Minimal islet mass trans-
plants allow for evaluation of technique efficacy with the 
minimal islet loading required to reverse diabetes. 
Encapsulated cells achieved diabetes reversal in diabetic 
10 mice with 500-600 syngeneic islet equivalents (IEQ) (FIG. 
4C). 
The high potential of synthetic hydrogel microencapsula-
tion for cell and protein therapeutics has been limited by the 
lack of synthetic polymer systems with tunable capsule size, 
cytocompatible crosslinking reactions, rapid crosslinking 
rates, adequate biomolecule permeability, and ease of func-
tionalization with bioactive molecules (e.g., adhesive pep-
tides). Using a synthetic hydrogel system with tunable net-
work and crosslinking characteristics and a microfluidics 
encapsulation platform, an integrated and robust strategy for 
microencapsulation of cells with tunable capsule size and 
local cellular microenvironment was created. Additionally, 15 
microgel network structure can be modulated to affect the 
permeability of the capsule to molecules of various sizes. 
Example 5 
Cell Performance can be Modulated by Altering 
Encapsulation Dynamics 
20 
Example 6 
Controlled Release of Cargo Encapsulated in 
Microfluidic-Generated Biodegradable Microgel 
Droplets 
Materials and Methods 
Preparation ofMicrofluidic Device 
Silicon masters fabricated by the Stanford Microfluidics 
Foundry were used to cast PDMS microfluidic devices with a 
25 flow focusing geometry and 200 µm nozzles. Devices were 
bounded to glass slides after an air plasma treatment. 
Initial microfluidic device prototypes featuring a 600 µm 
diameter liquid phase extrusion needle produced hydrogel 
capsules on the scale of the smallest capsules produced with 
established and traditional methods (200-600 µm). Subse-
quent prototype designs featuring a 400 µm diameter extru-
sion needle produced capsules in the range of 50-300 µm, 
which produces minimal void space and is the preferred for 30 
the application of islet encapsulation. Examples of islet-con-
taining capsules generated with both devices exhibited reduc-
tion in capsule size is evident, as well as a reduction in the 
number of islets contained per capsule (600 µm device rela-
tive to 400 µm devise). 
PEG-4MAL Microgel Formation 
Microfluidic devices with flow focusing geometry were 
used to form the polymer droplets in a water in oil emulsion. 
Two different solutions of macromer 5% PEG-4MAL 20 kDa 
and crosslinker (GPQ (W) or VPM or GPQ (A) peptides) 
were prepared in PBS at a PEG-4MAL:crosslinker molar 
For some embodiments, for example pancreatic islet 
microencapsulation for immunoisolation, it may be desirable 
to have smaller capsule sizes. The system was modulated to 
reduce capsule size to -300 µm without increasing incidence 
35 ratio of 2: 1. The pH of both solutions was fixed at 6.5 and 4.5 
respectively, without modification of the molar ratio, to con-
trol the kinetics of the gelation after contact of both phases in 
the microfluidic device. Devices with long outlet charmels 
of microfluidic channel clogging by utilizing a flow focusing 40 
device with a 400 µm nozzle. 
Characterization of microgel size vs inlet flow rates is 
illustrated in FIG. 4A. Utilizing flow rates that produce cap-
sules below 200 µm for islet encapsulation results in sporadic 
encapsulation of islets, because islets are excluded from cap- 45 
sules when flow is focused to dimensions smaller than islet 
size. 
were used to increase the residence time of the generated 
droplets inside the device, in order to ensure the microgel 
formation before the polymer droplets leave the device. The 
generated microgels were washed several times in PBS. 
Microgels Size 
Microgels generated by using different biodegradable 
crosslinkers were observed under an optical microscope and 
representative images of each microgel were recorded for 
posterior analysis. Microparticle diameter of at least 20 
microgels was measured for each crosslinker using ImageJ 
analysis software. 
Protein Encapsulation and Release 
Alexa fluor 488 IgG was encapsulated in PEG-4MAL 
hydrogels via microfluidics by using different crosslinkers. 
To do so, IgG protein was dissolved in 5% PEG-4MAL solu-
tion atlOO ug/ml and was posteriorly mixed, at a ratio of2:1, 
Smaller device dimensions allow for production of smaller 
microgels for islet encapsulation. Attempts at single cell 
encapsulation utilizing the platform were also successful. 50 
Single cells can be encapsulated in -50 µm capsules with low 
polydispersity if very dilute cell suspensions are used for 
encapsulation. However, cell throughput is can be compro-
mised under these conditions, leading to large numbers of 
empty capsules. At higher cell densities, however, satisfac-
tory cell throughput is obtained (approximately 5E5-1E6 
cells per second). Although some cells remain unencapsu-
lated, and some increase in capsule polydispersity is noted, 
most capsules containing cells have around 5-15 cells, and 
capsule size ranges from 40-100 µm. 
55 with the corresponding crosslinker solution in the microflu-
idic device before being encapsulated by macromer droplet 
formation. The pH of both solutions was fixed to control the 
kinetics of the crosslinking reaction. After microgel forma-
tion, microparticles were washed several times in PBS and 
It is believed that cell ordering charmels will further 
increase the efficiency of single cell encapsulation. This fea-
ture can be paired with scaled down microfluidic chips, 
enabling production of single-cell capsules with characteris-
tic size of approximately 20 µm. 
Islets encapsulated with both microfluidic devices exhib-
ited high cell viability (FIG. 4 B) and detectable insulin sec re-
60 resuspended in 3 ml of PBS. 
To evaluate the protein release from the microgels, the 
initial fluorescence of a 100 µl aliquot of the microparticle 
suspension was measured in a multimode plate reader. Col-
lagenase I at a final concentration of 100 ug/ml was added to 
65 the microparticles and the concentration of the released pro-
tein in the supernatant at different time points was quantified 
by measuring the fluorescence of 100 µl aliquots. 
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Results 
Macromer has a 4 arm PEG modified with a terminated 
maleimide group in each arm. Free thiol-containing mol-
ecules bind covalently to maleimide groups via Michael-type 
addition reaction (FIG. lA). A flow focusing microfluidic 
device with 200 µm nozzle is used to produce microgels and 
encapsulate proteins. FIG. SA is a schematic representation 
of the protein encapsulation via microfluidics on a flow focus-
ing device. The solution of macromer PEG-4MAL and pro-
tein to be encapsulated is mixed with the crosslinker phase 
10 before the droplet formation. After droplet formation, in the 
outlet charmel, peptide containing free cysteines reacts with 
the PEG-4MAL macromer to produce biodegradable 
crosslinked microgels. 
Cross linker 
GPQ (W) 
(SEQ ID NO, 
VPM 
GPQ (A) 
(SEQ ID NO, 
26 
Size 
434.4 ± 69.6 
2) 
386. 2 ± 51.4 
401. 6 ± 44. 4 
3) 
Different biodegradable crosslinkers were used to produce 
PEG-4MAL microgels: 
Biodegradable crosslinkers Peptide sequence Mw 
Alexa fluor 488 IgG secondary antibody was encapsulated 
in the different micro gels via microfluidics. The encapsulated 
protein was visualized using a confocal microscope and 
quantified by reading the fluorescence of a microparticle sus-
15 pension in a plate reader. The protein release from the differ-
ent microgels was evaluated over the time as they are 
degraded in the presence of protease (collagenase I) (FIG. 
SB). 
GPQ (W) (SEQ ID NO, 2) GCRDGPQGIWGQDRCG 1704.88 
(SEQ ID NO, 4) 
VPM GCRDVPMSMRGGDRCG 1696.99 
(SEQ ID NO, 5) 
GPQ (A) (SEQ ID NO, 3) GCRDGPQGIAGQDRCG 1589.74 
(SEQ ID NO, 6) 
A microfluidic device with flow focusing geometry was 
used to obtain monodisperse biodegradable hydrogel micro-
particles: 
<160> NUMBER OF SEQ ID NOS, 
<210> SEQ ID NO 1 
<211> LENGTH, 7 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 1 
Gly Arg Gly Asp Ser Pro Cys 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
20 
25 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
stood by one of skill in the art to which the disclosed invention 
belongs. Publications cited herein and the materials for which 
they are cited are specifically incorporated by reference. 
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
<223> OTHER INFORMATION, synthetic polypeptide (abbreviation for SEQ ID 
N0,4) 
<400> SEQUENCE, 2 
Gly Pro Gln Trp 
1 
<210> SEQ ID NO 3 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide (abbreviation for SEQ ID 
NO, 6) 
<400> SEQUENCE, 3 
Gly Pro Gln Ala 
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-continued 
1 
<210> SEQ ID NO 4 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 4 
Gly Cys Arg Asp Gly Pro Gln Gly Ile Trp Gly Gln Asp Arg Cys Gly 
1 5 10 15 
<210> SEQ ID NO 5 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 5 
Gly Cys Arg Asp Val Pro Met Ser Met Arg Gly Gly Asp Arg Cys Gly 
1 5 10 15 
<210> SEQ ID NO 6 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 
Gly Cys Arg Asp Gly Pro Gln Gly Ile Ala Gly Gln Asp Arg Cys Gly 
1 5 10 15 
We claim: 5. The method of claim 1, wherein the macromer is a four 
arm maleimide-linked polyethylene glycol (PEG-4MAL). 1. A method of encapsulating cargo in a microgel droplet 
comprising flowing a macromer phase, an oil phase, and a 
crosslinker phase through a flow focusing nozzle of a microf-
luidic device to form microgel droplets by oil and water 
emulsion, 
40 
6. The method of claim 5, wherein the crosslinker comprise 
a thiol that can be covalent crosslinked to the maleimide by a 
Michael-type additional reaction. 
wherein the macromer phase comprises a macromer and a 
cargo in aqueous buffer; the oil phase comprises an 
oil-phase oil and an oil-phase surfactant; and the 
crosslinker phase comprises a crosslinker-phase oil, a 
crosslinker-phase surfactant, and a crosslinking agent, 
7. The method of claim 6, wherein the crosslinker is dithio-
threitol (DTT) or a biodegradable peptide crosslinker com-
45 positing the amino acid sequence of SEQ ID N0:4, 5, or 6. 
8. The method of claim 7, wherein the PEG-4MAL is "N" 
wherein the phases are pumped, injected, or passaged 
through the microfluidic device such that as the mac-
romer phase approaches the flow focusing nozzle, the 50 
co-flowing oil phase shields the macromer from contact 
with the crosslinker phase until flow instability occurs 
and macromer phase droplets forms, 
wherein after flow instability occurs, the crosslinker dif-
fuses from the crosslinker phase into the droplets in an 55 
effective amount to covalently crosslink the macromer 
into a microgel droplet encapsulating the cargo, and 
wherein the crosslinking is not ultraviolet (UV) initiated 
photopolymerization. 
2. The method of claim 1, wherein the nozzle size and flow 60 
rates selected to produce droplets of a size between about 10 
µm and 1,000 µm, inclusive. 
3. The method of claim 2, wherein the flow rates of each of 
the phases is "X" nl/min, wherein "X" is an integer between 
about 100 and about 1,000,000. 
4. The method of claim 2, wherein the nozzle size 1s 
between about 50 µm and 1,000 µm, inclusive. 
65 
kDa wherein "N" is an integer between 1 and 50, inclusive. 
9. The method of claim 8, wherein the microgel droplet is 
permeable to small molecules, but not to cells. 
10. The method of claim 1, wherein the cargo encapsulated 
in each microgel droplet comprises one or more cells. 
11. The method of claim 10, wherein the cargo encapsu-
lated in each microgel droplet comprises a cluster of cells. 
12. The method of claim 11, wherein the cluster of cells is 
an islet of pancreatic beta cells. 
13. The method of claim 10, wherein the cells are stem 
cells. 
14. The method of claim 1, wherein the cargo encapsulated 
in each microgel droplet comprises one or more bioactive 
agents. 
15. The method of claim 14, wherein the one or more 
bioactive agents is selected from the group consisting of 
proteins, peptides, amino acids, nucleic acids, carbohydrates, 
lipids, small molecules, or combinations thereof. 
16. The method claim 15, wherein the permeability of the 
microgel droplet allows slow or extended release of the bio-
active agent. 
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17. The method of claim 8, wherein the macromer phase 
further comprises a bioactive agent comprising a thiol that is 
functionally linked to the macromer by a Michael-type addi-
tion reaction prior to crosslinking of the macromer into the 
microgel. 
18. The method claim 17, wherein the bioactive agent can 
be released from the microgel by a protease in vivo. 
* * * * * 
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